Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
The peptide's half-life of approximately 4 hours means twice-daily dosing (0.5mg morning and evening) may provide more consistent lipolytic activity, though single daily dosing proves effective for most women
Assessing adiposity: a scientific statement from the American Heart Association
Concomitant medicines particularly insulin or sulfonylureas should be reviewed for interaction risk, and pregnancy or breastfeeding status should be assessed
Personalized hormone therapy for women Work with a licensed provider to find the right hormone optimization plan for your symptoms and goals
Garvey, W
US$ 22.33
US$ 21.73
US$ 24.24
US$ 27.77
